Hem › Magsäckscancer › Tennessee
Kliniska studier för Magsäckscancer i Tennessee
30 studier för Magsäckscancer söker deltagare vid platser i Tennessee.
Städer i Tennessee
Officiell studietext (engelska)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- SCRI Oncology Partners, Nashville
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT06760819Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- Baptist Memorial Hospital and Cancer Center-Collierville, Collierville
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
RekryterarFriska volontärer välkomna
Ålder 18 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT07283939A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- SCRI Oncology Partners, Nashville
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT06172478A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Sarah Cannon Research Institute (SCRI), Nashville
RekryterarFas 1
Ålder 19 och äldre · Alla kön · Uppdaterad 1 okt. 2026 · NCT06586957A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
RekryterarFas 2/3
Ålder 18 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT07221149Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Sarah Cannon Research Institute (SCRI) - Oncology Partners, Nashville
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 29 sep. 2026 · NCT07700979IKS014 in Advanced Solid Tumors That Express HER2
- Tennessee Oncology, Nashville
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT05872295Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Vanderbilt University Medical Center, Nashville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 24 sep. 2026 · NCT06047379Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- Vanderbilt Ingram Cancer Center, Nashville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 24 sep. 2026 · NCT05523947Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Nashville
RekryterarFas 2
Ålder 18 till 130 · Alla kön · Uppdaterad 23 sep. 2026 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Sarah Cannon Research Institue, Nashville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT06128551Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Sarah Cannon Research Institute, Nashville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 18 sep. 2026 · NCT05267626Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Sarah Cannon Research Institute, Nashville
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 10 sep. 2026 · NCT06293898Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Nashville
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 9 sep. 2026 · NCT07431281A Phase 1/1b Study of IAM1363 in HER2 Cancers
- SCRI Oncology Partners, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 9 sep. 2026 · NCT06253871A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 13 aug. 2026 · NCT07066657A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 11 aug. 2026 · NCT05592626A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- The University Of Tennessee Health Science Center, Memphis
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 29 juli 2026 · NCT03526835A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 22 juli 2026 · NCT06131840A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 15 juli 2026 · NCT06657144A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- SCRI Oncology Partners, Nashville
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 10 juli 2026 · NCT06695845A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- US Oncology Research LLC, Nashville
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 6 juli 2026 · NCT04389632Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
- Vanderbilt University Medical Center, Nashville
RekryterarTidig fas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 8 maj 2026 · NCT06828588Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 6 maj 2026 · NCT06239194Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
- Veterans Affairs Medical Center - Nashville, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
RekryterarObservationsstudie
Ålder 18 och äldre · Alla kön · Uppdaterad 5 mars 2026 · NCT00899626A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Vanderbilt University Medical Center, Nashville
- HCA Midwest Health, Nashville
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 27 feb. 2026 · NCT06532006A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
- Sarah Cannon Research Institute, Nashville
RekryterarFas 1/2
Ålder 18 till 85 · Alla kön · Uppdaterad 29 jan. 2026 · NCT06055439cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
RekryterarObservationsstudieFriska volontärer välkomna
Ålder 40 och äldre · Alla kön · Uppdaterad 20 jan. 2026 · NCT05366881SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 28 okt. 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Tennessee Oncology, Nashville
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 24 sep. 2025 · NCT05941507Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.